1
|
Spigel D, Galsky M, Heeke A, Villaruz L, Sands J, Subbiah V, Sonpavde G, Singh A, Srinivas S, Brock G, Cai G, Bhatt K, Chakrabarti D. PP01.50 EMERGE-201: Phase 2 Basket Study of Lurbinectedin Monotherapy in Advanced or Metastatic Solid Tumors. J Thorac Oncol 2023. [DOI: 10.1016/j.jtho.2022.09.076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
|
2
|
Muralidhar V, Carvalho F, Preston M, Curran C, Freeman D, Sonpavde G, Kibel A, Van Allen E, Mossanen M, Mouw K. Genomic Features of Radiation-Associated Muscle-Invasive Bladder Cancer. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
3
|
Sonpavde G, Koshkin V, Hwang C, Mellado B, Tomlinson G, Shimura M, Chisamore M, Gil M, Loriot Y. A phase 2 study of futibatinib plus pembrolizumab in patients (pts) with advanced or metastatic urothelial carcinoma (mUC). EUR UROL SUPPL 2021. [DOI: 10.1016/s2666-1683(21)03206-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
4
|
Loriot Y, Vuillet M, Mamtani R, Rosenberg J, Powles T, Sonpavde G, Duran I, Lee J, Matsubara N, Vulsteke C, Castellano D, Sridhar S, Pappo H, Valderram B, Gurney H, Bedke J, Van der heijden M, Hepp Z, Petrylak D. Qualité de vie et symptômes chez les patients atteints d’un carcinome urothélial localement avancé ou métastatique précédemment traité de l’étude Ev-301 : une étude randomisée de phase 3 comparant enfortumab vedotin à la chimiothérapie. Prog Urol 2021. [DOI: 10.1016/j.purol.2021.08.112] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
5
|
Montazeri K, Dranitsaris G, Thomas JD, Curran C, Preston MA, Steele GS, Kilbridge KL, Mantia C, Ravi P, McGregor BA, Mossanen M, Sonpavde G. An economic analysis comparing health care resource use and cost of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin versus gemcitabine and cisplatin as neoadjuvant therapy for muscle invasive bladder cancer. Urol Oncol 2021; 39:834.e1-834.e7. [PMID: 34162500 DOI: 10.1016/j.urolonc.2021.04.032] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2021] [Revised: 04/11/2021] [Accepted: 04/23/2021] [Indexed: 12/09/2022]
Abstract
PURPOSE To compare healthcare resource utilization (HRU) and costs associated with dose-dense methotrexate, vinblastine, doxorubicin, cisplatin (ddMVAC) and gemcitabine, cisplatin (GC) as neoadjuvant chemotherapy for muscle-invasive bladder cancer (MIBC). METHODS Patient treated at Dana-Farber Cancer Institute from 2010 to 2019 were identified. HRU data on chemotherapy administered, supportive medications, patient monitoring, clinic, infusion, emergency department (ED) visits and hospitalization were collected retrospectively. Unit costs for HRU components were obtained from the Centers for Medicare and Medicaid Website and HRU was compared between groups using quantile regression analysis. RESULTS 137 patients were included; 51 received ddMVAC and 86 GC. Baseline characteristics were similar, except lower mean age (P < 0.001) and higher proportion of ECOG-PS = 0 (P < 0.001) for ddMVAC. ddMVAC required more granulocyte-colony stimulating factor support (P < 0.001), central line placement (P = 0.017), cardiac imaging (P < 0.001), and infusion visits (P < 0.001), whereas GC required more clinic visits. ED visits were higher for ddMVAC (P = 0.048), while chemotherapy cycle delays and hospitalization days were higher for GC (P = 0.008). After adjusting for ECOG-PS and age, the cost per patient was approximately 41% lower (95%CI: 28% to 52%; P < 0.001) for GC vs. ddMVAC, which translated to a median adjusted cost savings of $7,410 (95%CI: $5,474-$9,347) per patient. CONCLUSIONS Although excess HRU did not clearly favor one regimen, adjusting for PS and age indicated lower costs with GC vs. ddMVAC. Given the similar cumulative cisplatin delivery with both regimens, the associated values and costs supports the preferential selection of GC in the neoadjuvant setting of MIBC.
Collapse
Affiliation(s)
- K Montazeri
- Massachusetts General Hospital, Boston, MA; Harvard Medical School, Boston, MA
| | | | - J D Thomas
- Beth Israel Deaconess Medical Center, Boston, MA
| | - C Curran
- Beth Israel Deaconess Medical Center, Boston, MA
| | - M A Preston
- Department of Urology, Brigham and Women's Hospital, Boston, MA
| | - G S Steele
- Department of Urology, Brigham and Women's Hospital, Boston, MA
| | - K L Kilbridge
- Department of Urology, Brigham and Women's Hospital, Boston, MA
| | - C Mantia
- Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, MA
| | - P Ravi
- Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, MA
| | - B A McGregor
- Beth Israel Deaconess Medical Center, Boston, MA
| | - M Mossanen
- Department of Urology, Brigham and Women's Hospital, Boston, MA
| | - G Sonpavde
- Beth Israel Deaconess Medical Center, Boston, MA.
| |
Collapse
|
6
|
Somford D, Daneshmand S, Grivas P, Sridhar S, Gupta S, Bellmunt J, Sonpavde G, Fleming M, Lerner S, Loriot Y, Li A, Takkele H, Andresen C, Rearden J, Peacock Shepherd S, Schnabel M, Pal S. 799TiP PROOF 302: A randomized, double-blind, placebo-controlled, phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring susceptible FGFR3 alterations. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.2070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
7
|
Armstrong AJ, Lin P, Higano CS, Sternberg CN, Sonpavde G, Tombal B, Templeton AJ, Fizazi K, Phung D, Wong EK, Krivoshik A, Beer TM. Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer. Ann Oncol 2019; 29:2200-2207. [PMID: 30202945 DOI: 10.1093/annonc/mdy406] [Citation(s) in RCA: 40] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
Abstract
Background Prognostic models are needed that reflect contemporary practice for men with metastatic castration-resistant prostate cancer (mCRPC). We sought to identify predictive and prognostic variables for overall survival (OS) in chemotherapy-naïve men with mCRPC treated with enzalutamide. Patients and methods Patients from the PREVAIL trial database (enzalutamide versus placebo) were randomly split 2 : 1 into training (n = 1159) and testing (n = 550) sets. Using the training set, 23 predefined variables were analyzed and a multivariable model predicting OS was developed and validated in an independent testing set. Results Patient characteristics and outcomes were well balanced between training and testing sets; median OS was 32.7 months in each. The final validated multivariable model included 11 independent prognostic variables. Median OS for low-, intermediate-, and high-risk groups (testing set) defined by prognostic risk tertiles were not yet reached (NYR) (95% CI NYR-NYR), 34.2 months (31.5-NYR), and 21.1 months (17.5-25.0), respectively. Hazard ratios (95% CI) for OS in the low- and intermediate-risk groups versus high-risk group were 0.20 (0.14-0.29) and 0.40 (0.30-0.53), respectively. Secondary outcomes of response and progression differed widely in model-defined risk groups. Enzalutamide improved outcomes in all prognostic risk groups. Conclusions Our validated prognostic model incorporates variables routinely collected in chemotherapy-naïve men with mCRPC treated with enzalutamide, identifying subsets of patients with widely differing survival outcomes that provide useful information for external validation, patient care, and clinical trial design. Trial registration ClinicalTrials.gov: NCT01212991.
Collapse
Affiliation(s)
- A J Armstrong
- Division of Medical Oncology and Urology, Duke Prostate and Urologic Cancer Center, Duke Cancer Institute Duke University, Durham.
| | - P Lin
- Biostatistics (Lin) and Medical Affairs (Wong), Pfizer Inc, San Francisco
| | - C S Higano
- Medical Oncology, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, USA
| | - C N Sternberg
- Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy
| | - G Sonpavde
- Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, USA
| | - B Tombal
- Urology, Cliniques universitaires Saint-Luc, Brussels, Belgium
| | - A J Templeton
- Department of Oncology, St. Claraspital and University of Basel, Basel, Switzerland
| | - K Fizazi
- Department of Cancer Medicine, Institut Gustave Roussy University of Paris Sud, Villejuif, France
| | - D Phung
- Biostatistics, Astellas Pharma Europe BV, Leiden, The Netherlands
| | - E K Wong
- Biostatistics (Lin) and Medical Affairs (Wong), Pfizer Inc, San Francisco
| | - A Krivoshik
- Medical Sciences, Astellas Pharma US, Inc, Northbrook
| | - T M Beer
- Hematology/Medical Oncology, OHSU Knight Cancer Institute Oregon Health & Science University, Portland, USA
| |
Collapse
|
8
|
Petrylak D, Rosenberg J, Lee J, Yonese J, Duran I, Loriot Y, Sonpavde G, Wu C, Gartner E, Melhem-Bertrandt A, Powles T. EV-301: A phase III trial in progress evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz425.014] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
9
|
Vaishampayan U, Heilbrun L, Monk P, Sonpavde G, Tejwani S, Heath E, Fontana J, Chinni S. Randomized trial of androgen deprivation therapy (ADT) + enzalutamide (Arm A) versus ADT + bicalutamide (Arm B) in metastatic hormone sensitive prostate cancer (mHSPC). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy284.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
10
|
Petrylak D, Rosenberg J, Duran I, Loriot Y, Sonpavde G, Wu C, Gartner E, Melhem-Bertrandt A, Powles T. EV-301: An open-label, randomized phase III study to evaluate enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy283.131] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
11
|
Caetano SJ, Sonpavde G, Pond GR. C-statistic: A brief explanation of its construction, interpretation and limitations. Eur J Cancer 2017; 90:130-132. [PMID: 29221899 DOI: 10.1016/j.ejca.2017.10.027] [Citation(s) in RCA: 85] [Impact Index Per Article: 12.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2017] [Accepted: 10/23/2017] [Indexed: 11/18/2022]
Affiliation(s)
- S J Caetano
- Department of Mathematics and Statistics, McMaster University, Hamilton, ON, Canada.
| | - G Sonpavde
- Dana Farber Cancer Institute, Boston, MA, USA
| | - G R Pond
- Department of Mathematics and Statistics, McMaster University, Hamilton, ON, Canada; Department of Oncology, McMaster University, Hamilton, ON, Canada
| |
Collapse
|
12
|
Agarwal N, Pal S, Sonpavde G, Kiedrowski L, Nagy R, Banks K, Lanman R, Grivas P. Comparison of circulating tumor DNA (ctDNA) profile in metastatic urothelial carcinoma (mUC) derived from the upper tract (UT) and lower tract (LT). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx371.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
13
|
Seisen T, Sonpavde G, Kachroo N, Lipsitz S, Leow J, Menon M, Gild P, Von Landenberg N, Rouprêt M, Kibel A, Sun M, Pal S, Bellmunt J, Choueiri T, Trinh QD. Comparative effectiveness of selective adjuvant versus systematic neoadjuvant chemotherapy-based strategy for muscle-invasive urothelial carcinoma of the bladder. ACTA ACUST UNITED AC 2017. [DOI: 10.1016/s1569-9056(17)30239-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
14
|
Petrylak D, Heath E, Sonpavde G, George S, Morgans A, Eigl B, Picus J, Cheng S, Hotte S, Gartner E, Vincent M, Chu R, Anand B, Morrison K, Jackson L, Melhem-Bertrandt A, Yu E. Interim analysis of a phase I dose escalation trial of the antibody drug conjugate (ADC) AGS15E (ASG-15ME) in patients (Pts) with metastatic urothelial cancer (mUC). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw373.08] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
15
|
Choueiri T, Michaelson M, Posadas E, Sonpavde G, McDermott D, Seon B, Jivani M, Shazer R, Adams B, Theuer C. A phase 1b dose-escalation study of TRC105 (endoglin antibody) in combination with axitinib in patients with metastatic renal cell carcinoma (mRCC). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw373.32] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
16
|
Dizman N, Pal S, Nelson R, Hsu J, Bergerot P, Nix J, Sonpavde G. Impact of race on survival following radical cystectomy for muscle-invasive bladder cancer (MIBC): Analysis of the US National Cancer Database (NCDB). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw373.22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
17
|
Pal S, Galsky M, Lin SW, Ogale S, Zivkovic M, Simpson J, Derleth C, Sonpavde G. Second-line metastatic urothelial carcinoma treatment and survival in real-world patients in the US. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw373.29] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
18
|
de Wit R, Kamat A, Bellmunt J, Choueiri T, Nam K, De Santis M, Dreicer R, Hahn N, Perini R, Siefker-Radtke A, Sonpavde G, Witjes J, Keefe S, Bajorin D. Pembrolizumab in patients with Bacillus Calmette Guérin (BCG)-unresponsive, high-risk non–muscle-invasive bladder cancer (NMIBC): Phase 2 KEYNOTE-057 study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw373.76] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
19
|
Necchi A, Sonpavde G, Vullo S, Bamias A, Crabb S, Harshman L, Bellmunt J, De Giorgi U, Sternberg C, Ladoire S, Wong YN, Yu E, Chowdhury S, Niegisch G, Srinivas S, Vaishampayan U, Pal S, Rosenberg J, Mariani L, Galsky M. Nomogram-based prediction of overall survival (OS) of patients (pts) with metastatic urothelial carcinoma (UC) receiving first-line platinum-based chemotherapy: retrospective international study of invasive/advanced cancer of the urothelium (RISC). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw373.25] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
20
|
Necchi A, Pond G, Raggi D, Ottenhof S, Horenblas S, Khoo V, Hakenberg O, Heidenreich A, Eigl B, Nappi L, Matsumoto K, Vaishampayan U, Woods M, Giannatempo P, Geynisman D, Preto M, Xylinas E, Milowsky M, Di Lorenzo G, Sonpavde G. Outcomes of peri-operative chemotherapy (PO-CT) for locally advanced penile squamous cell carcinoma (LA-PSCC): results from a multicenter analysis. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw373.66] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
21
|
Sonpavde G, Pond GR, Templeton AJ, Kwon ED, De Bono JS. Impact of single-agent daily prednisone on outcomes in men with metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 2016; 20:67-71. [DOI: 10.1038/pcan.2016.44] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2016] [Revised: 05/27/2016] [Accepted: 06/16/2016] [Indexed: 12/17/2022]
|
22
|
Sonpavde G, Pond GR, Di Lorenzo G, Buonerba C, Rozzi A, Lanzetta G, Necchi A, Giannatempo P, Raggi D, Matsumoto K, Choueiri TK, Mullane S, Niegisch G, Albers P, Lee JL, Kitamura H, Kume H, Bellmunt J. Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial Carcinoma. Clin Genitourin Cancer 2016; 14:494-498. [PMID: 27262369 DOI: 10.1016/j.clgc.2016.05.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2016] [Accepted: 05/06/2016] [Indexed: 11/24/2022]
Abstract
BACKGROUND Trials of salvage therapy for advanced urothelial carcinoma have required prior platinum-based therapy. This practice requires scrutiny because non-platinum-based first-line therapy may be offered to cisplatin-ineligible patients. PATIENTS AND METHODS Data of patients receiving salvage systemic chemotherapy were collected. Data on prior first-line platinum exposure were required in addition to treatment-free interval, hemoglobin, Eastern Cooperative Oncology Group performance status, albumin, and liver metastasis status. Cox proportional hazard regression was used to evaluate their association with overall survival (OS) after accounting for salvage single-agent or combination chemotherapy. RESULTS Data were obtained from 455 patients previously exposed to platinum-based therapy and 37 not exposed to platinum. In the group exposed to prior platinum therapy, salvage therapy consisted of a single-agent taxane (n = 184) or a taxane-containing combination chemotherapy (n = 271). In the group not exposed to prior platinum therapy, salvage therapy consisted of taxane or vinflunine (n = 20), 5-fluorouracil (n = 1), taxane-containing combination chemotherapy (n = 12), carboplatin-based combinations (n = 2), and cisplatin-based combinations (n = 2). The median OS for the prior platinum therapy group was 7.8 months (95% confidence interval, 7.0, 8.1), and for the group that had not received prior platinum therapy was 9.0 months (95% confidence interval, 6.0, 11.0; P = .50). In the multivariable analysis, prior platinum therapy versus no prior platinum exposure did not confer an independent impact on OS (hazard ratio, 1.10; 95% confidence interval, 0.75, 1.64; P = .62). CONCLUSION Prior platinum- versus non-platinum-based chemotherapy did not have a prognostic impact on OS after accounting for major prognostic factors in patients receiving salvage systemic chemotherapy for advanced urothelial carcinoma. Lack of prior platinum therapy should not disqualify patients from inclusion onto trials of salvage therapy.
Collapse
Affiliation(s)
- G Sonpavde
- UAB Comprehensive Cancer Center, Birmingham, AL.
| | - G R Pond
- McMaster University, Hamilton, Ontario, Canada
| | | | - C Buonerba
- Centro di Riferimento Oncologico della Basilicata IRCCS, Rionero in Vulture, Italy
| | - A Rozzi
- Istituto Neurotraumatologico Italiano, Grottaferrata, Italy
| | - G Lanzetta
- Istituto Neurotraumatologico Italiano, Grottaferrata, Italy
| | - A Necchi
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - P Giannatempo
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - D Raggi
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - K Matsumoto
- Kitasato University School of Medicine, Sagamihara, Japan
| | - T K Choueiri
- Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA
| | - S Mullane
- Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA
| | - G Niegisch
- Heinrich Heine University, Medical Faculty, Dusseldorf, Germany
| | - P Albers
- Heinrich Heine University, Medical Faculty, Dusseldorf, Germany
| | - J L Lee
- Asan Medical Center, Seoul, South Korea
| | - H Kitamura
- Sapporo Medical University School of Medicine, Sapporo, Japan
| | - H Kume
- University of Tokyo Hospital, Tokyo, Japan
| | - J Bellmunt
- Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA
| |
Collapse
|
23
|
Sonpavde G, Anderson J, Naik G, Grizzle W, Willey C. Functional activity of kinases in muscle-invasive bladder cancer to identify potentially actionable therapeutic targets. Eur J Cancer 2016. [DOI: 10.1016/j.ejca.2016.03.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
24
|
Raggi D, Miceli R, Sonpavde G, Giannatempo P, Mariani L, Galsky MD, Bellmunt J, Necchi A. Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis. Ann Oncol 2015; 27:49-61. [PMID: 26487582 DOI: 10.1093/annonc/mdv509] [Citation(s) in RCA: 80] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2015] [Accepted: 10/12/2015] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND The efficacy and safety of a combination of chemotherapeutic agent compared with single-agent chemotherapy in the second-line setting of advanced urothelial carcinoma (UC) are unclear. We aimed to study the survival impact of single-agent compared with doublet chemotherapy as second-line chemotherapy of advanced UC. PATIENTS AND METHODS Literature was searched for studies including single-agent or doublet chemotherapy in the second-line setting after platinum-based chemotherapy. Random-effects models were used to pool trial-level data according to treatment arm, including median progression-free survival (PFS), overall survival (OS), objective response rate (ORR) probability, and grade 3-4 toxicity. Univariable and multivariable analyses, including sensitivity analyses, were carried out, adjusting for the percent of patients with ECOG performance status ≥1 and hepatic metastases. RESULTS Forty-six arms of trials including 1910 patients were selected: 22 arms with single agent (n = 1202) and 24 arms with doublets (n = 708). The pooled ORR with single agents was 14.2% [95% confidence interval (CI) 11.1-17.9] versus 31.9% [95% CI 27.3-36.9] with doublet chemotherapy. Pooled median PFS was 2.69 and 4.05 months, respectively. The pooled median OS was 6.98 and 8.50 months, respectively. Multivariably, the odds ratio for ORR and the pooled median difference of PFS were statistically significant (P < 0.001 and P = 0.002) whereas the median difference in OS was not (P = 0.284). When including single-agent vinflunine or taxanes only, differences were significant only for ORR (P < 0.001) favoring doublet chemotherapy. No statistically significant differences in grade 3-4 toxicity were seen between the two groups. CONCLUSIONS Despite significant improvements in ORR and PFS, doublet regimens did not extend OS compared with single agents for the second-line chemotherapy of UC. Prospective trials are necessary to elucidate the role of combination chemotherapy, with or without targeted agents, in the salvage setting. Currently, improvements in this field should be pursued considering single-agent chemotherapy as the foundation for new more active combinations.
Collapse
Affiliation(s)
- D Raggi
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - R Miceli
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - G Sonpavde
- UAB Comprehensive Cancer Center, Birmingham
| | - P Giannatempo
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - L Mariani
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - M D Galsky
- Mount Sinai School of Medicine, Tisch Cancer Institute, New York
| | - J Bellmunt
- Dana-Farber Cancer Institute and Harvard Medical School, Boston, USA
| | - A Necchi
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| |
Collapse
|
25
|
Necchi A, Giannatempo P, Pond G, Raggi D, Nicolai N, Salvioni R, Procopio G, De Braud F, Sonpavde G. Gemcitabine and Platinum (GC) chemotherapy alone or with a Taxane (GC-T) as first-line therapy for urothelial cancer (UC): a meta-analysis. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv341.09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
26
|
Raggi D, Miceli R, Sonpavde G, Giannatempo P, Nicolai N, Salvioni R, Procopio G, De Braud F, Mariani L, Necchi A. Single agent versus doublet chemotherapy as second-line therapy of metastatic urothelial carcinoma (UC): a meta-analysis. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv341.08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
27
|
Galsky M, Pal S, Lin S, Ogale S, Simpson J, Schiff C, Sonpavde G. 2624 The effectiveness of chemotherapy in “real world” patients with metastatic bladder cancer. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31442-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
28
|
Giannatempo P, Greco T, Mariani L, Nicolai N, Tana S, Farè E, Raggi D, Piva L, Catanzaro M, Biasoni D, Torelli T, Stagni S, Avuzzi B, Maffezzini M, Landoni G, De Braud F, Gianni A, Sonpavde G, Salvioni R, Necchi A. Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systematic review and meta-analysis of patient outcomes. Ann Oncol 2015; 26:657-668. [DOI: 10.1093/annonc/mdu447] [Citation(s) in RCA: 51] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
|
29
|
van Soest R, Templeton A, Vera-Badillo F, Mercier F, Sonpavde G, Amir E, Tombal B, Rosenthal M, Eisenberger M, Tannock I, de Wit R. Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials. Ann Oncol 2015; 26:743-749. [DOI: 10.1093/annonc/mdu569] [Citation(s) in RCA: 103] [Impact Index Per Article: 11.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
|
30
|
Pond G, Bellmunt J, Rosenberg J, Bajorin D, Regazzi A, Choueiri T, Qu A, Niegisch G, Albers P, Necchi A, Di Lorenzo G, Fougeray R, Wong YN, Sridhar S, Ko YJ, Milowsky M, Galsky M, Sonpavde G. Impact of the Number of Prior Lines of Therapy and Prior Perioperative Chemotherapy in Patients Receiving Salvage Therapy for Advanced Urothelial Carcinoma: Implications for Trial Design. Clin Genitourin Cancer 2015; 13:71-9. [DOI: 10.1016/j.clgc.2014.06.004] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2014] [Revised: 04/29/2014] [Accepted: 06/03/2014] [Indexed: 11/16/2022]
|
31
|
Sonpavde G, Necchi A, Giannatempo P, Di Lorenzo G, Eigl B, Locke J, Pal S, Agarwal N, Poole A, Vaishampayan U, Niegisch G, Hussain S, Singh P, Bellmunt J, Pond G. Outcomes with Cisplatin-Based First-Line Therapy for Advanced Urothelial Carcinoma (Uc) Following Previous Perioperative Cisplatin-Based Therapy. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu337.60] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
32
|
Sonpavde G, Ghatalia P, Je Y, Kaymakcalan M, Choueiri T. Qtc Interval Prolongation with Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: a Systematic Review and Meta-Analysis. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu356.4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
33
|
Sonpavde G, Bellmunt J, Rosenberg J, Bajorin D, Regazzi A, Choueiri T, Qu A, Niegisch G, Albers P, Necchi A, Di Lorenzo G, Fougeray R, Dreicer R, Wong Y, Sridhar S, Ko Y, Milowsky M, Galsky M, Pond G. The Significance of Complete Response (Cr) in Patients Receiving Salvage Therapy for Advanced Urothelial Carcinoma (Uc). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu337.58] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
34
|
Abstract
The therapeutic landscape of metastatic castration-resistant prostate cancer (mCRPC) has been revolutionized by the arrival of multiple novel agents in the past 2 years. Immunotherapy in the form of sipuleucel-T, androgen axis inhibitors, including abiraterone acetate and enzalutamide, a chemotherapeutic agent, cabazitaxel, and a radiopharmaceutical, radium-223, have all yielded incremental extensions of survival and have been recently approved. A number of other agents appear promising in early studies, suggesting that the armamentarium against castrate-resistant prostate cancer is likely to continue to expand. Emerging androgen pathway inhibitors include androgen synthesis inhibitors (TAK700), androgen receptor inhibitors (ARN-509, ODM-201), AR DNA binding domain inhibitors (EPI-001), selective AR downregulators or SARDs (AZD-3514), and agents that inhibit both androgen synthesis and receptor binding (TOK-001/galeterone). Promising immunotherapeutic agents include poxvirus vaccines and CTLA-4 inhibitor (ipilimumab). Biologic agents targeting the molecular drivers of disease are also being investigated as single agents, including cabozantinib (Met and VEGFR2 inhibitor) and tasquinimod (angiogenesis and immune modulatory agent). Despite the disappointing results seen from studies evaluating docetaxel in combination with other agents, including GVAX, anti-angiogentic agents (bevacizumab, aflibercept, lenalinomide), a SRC kinase inhibitor (dasatinib), endothelin receptor antagonists (atrasentan, zibotentan), and high-dose calcitriol (DN-101), the results from the trial evaluating docetaxel in combination with the clusterin antagonist, custirsen, are eagerly awaited. New therapeutic hurdles consist of discovering new targets, understanding resistance mechanisms, the optimal sequencing and combinations of available agents, as well as biomarkers predictive for benefit. Novel agents targeting bone metastases are being developed following the success of zoledronic acid and denosumab. Finally, all of these modalities do not appear curative, suggesting that clinical trial enrollment and a better understanding of biology remain of paramount importance.
Collapse
Affiliation(s)
- N Agarwal
- Division of Medical Oncology, University of Utah Huntsman Cancer Institute, Salt Lake City, USA
| | - G Di Lorenzo
- Department of Endocrinology and Medical Oncology, Genitourinary Cancer Section, University Federico II, Napoli, Italy
| | - G Sonpavde
- Department of Medicine, Division of Hematology Oncology, University of Alabama at Birmingham (UAB) Comprehensive Cancer Center, Birmingham
| | - J Bellmunt
- Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, USA and; University Hospital del Mar-IMIM, Barcelona, Spain.
| |
Collapse
|
35
|
Pal S, Azad A, Bhatia S, Drabkin H, Costello B, Sarantopolous J, Kanesvaran R, Lauer R, Sweeney C, Hahn N, Sonpavde G, Richey S, Breen T, Kremmidiotis G, Doolin E, Bibby D, Simpson J, Iglesias J, Hutson T. A Phase I/II Trial of Bnc105P with Everolimus in Metastatic Renal Cell Carcinoma (Mrcc): Results of the Randomized Phase Ii Disruptor-1 Trial. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu337.8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
36
|
Choueiri TK, Je Y, Sonpavde G, Richards CJ, Galsky MD, Nguyen PL, Schutz F, Heng DY, Kaymakcalan MD. Incidence and risk of treatment-related mortality in cancer patients treated with the mammalian target of rapamycin inhibitors. Ann Oncol 2013; 24:2092-7. [PMID: 23658373 DOI: 10.1093/annonc/mdt155] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND Inhibition of the mammalian target of rapamycin (mTOR) is an established treatment for multiple malignancies. We carried out an up-to-date meta-analysis to determine the risk of fatal adverse events (FAEs) in cancer patients treated with mTOR inhibitors. PATIENTS AND METHODS PubMed, conferences and clinicaltrials.gov databases were searched for articles reported from January 1966 to June 2012. Eligible studies were limited to approved mTOR inhibitors (everolimus and temsirolimus) and reported on patients with cancer, randomized design and adequate safety profiles. Data extraction was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. RESULTS In all, 3193 patients from eight randomized, controlled trials (RCTs) were included, 2236 from everolimus trials and 957 from temsirolimus trials. The relative risk (RR) of FAEs related to mTOR inhibitors use was 2.20 (95% CI, 1.25-3.90; P = 0.006) compared with control patients. On subgroup analysis, no difference in the rate of FAEs was found between everolimus and temsirolimus or between tumor types [renal cell carcinoma (RCC) versus non-RCC]. No evidence of publication bias was observed. CONCLUSION The use of mTOR inhibitors is associated with a small but higher risk of FAEs compared to control patients. In the appropriate clinical scenario, the use of these drugs remains justified in their approved indications.
Collapse
Affiliation(s)
- T K Choueiri
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Abstract
Background Penile cancer (PC) is a rare cancer in western countries, but is more common in parts of the developing world. Due to its rarity and the consequent lack of randomized trials, current therapy is based on retrospective studies and small prospective trials. Design Studies of PC therapy were searched in PubMed and abstracts at major conferences. Results PC is generally an aggressive malignancy characterized by early locoregional lymph node (LN) spread and later metastases in distant sites. Given the strong predictive value of LN involvement for overall survival, evaluating regional LNs is critical. Advanced LN involvement is increasingly being treated with multimodality therapy incorporating chemotherapy and/or radiation. A single superior cisplatin-based regimen has not been defined. Further advances may occur with a better collaboration on an international scale and comprehensive understanding of tumor biology. To this end, the preventive role of circumcision and understanding of the oncogenic roles of Human Papilloma Virus-16, and smoking may yield advances. Preliminary data suggest a role for agents targeting epidermal growth factor receptor and angiogenesis. Conclusion Advances in therapy for PC will require efficient trial designs, synergistic collaboration, incentives to industry and the efforts of patient advocacy groups and venture philanthropists.
Collapse
Affiliation(s)
- G Sonpavde
- Department of Medicine, Section of Medical Oncology, UAB Comprehensive Cancer Center, Birmingham
| | | | | | | | | | | |
Collapse
|
38
|
Sonpavde G, Choueiri TK. Biomarkers: the next therapeutic hurdle in metastatic renal cell carcinoma. Br J Cancer 2012; 107:1009-16. [PMID: 22948724 PMCID: PMC3461173 DOI: 10.1038/bjc.2012.399] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2012] [Revised: 05/18/2012] [Accepted: 06/14/2012] [Indexed: 12/20/2022] Open
Abstract
Despite recent advances, metastatic renal cell carcinoma remains largely an incurable disease. Vascular endothelial growth factor and mammalian target of rapamycin inhibitors have provided improvements in clinical outcomes. High-dose interleukin 2 remains an option for highly selected patients and is associated with durable remissions in a small minority of patients. The toxicity profiles of specific agents and patient characteristics and comorbidities and costs have an important role in the current choice of therapy. Major challenges encountered in developing molecular biomarkers to guide therapy are tumour heterogeneity and standardisation of tissue collection and analysis. Although biomarkers are in their infancy of development, they should be a priority in early preclinical and clinical development in order to guide rational tailored development of emerging agents.
Collapse
Affiliation(s)
- G Sonpavde
- Urologic Medical Oncology, University of Alabama at Birmingham (UAB) Comprehensive Cancer Center, Birmingham, AL 35294, USA
| | - T K Choueiri
- Kidney Cancer Center, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave., Boston, MA 02215, USA
| |
Collapse
|
39
|
Sonpavde G, Pond G, Armstrong A, Galsky M, Wood B, Wang S, Paolini J, Lechuga M, Smith M, Michaelson M. Association of Progression by Prostate Cancer Working Group (PCWG)-2 Criteria and Survival in Metastatic Castration Resistant Prostate Cancer. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33529-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
40
|
Sonpavde G, Matveev V, Burke J, Caton J, Fleming M, Hutson T, Galsky M, Berry W, Karlov P, Holmlund J, Wood B, Brookes M, Leopold L. Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer. Ann Oncol 2012; 23:1803-8. [DOI: 10.1093/annonc/mdr555] [Citation(s) in RCA: 111] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
41
|
de Bono JS, Molife LR, Sonpavde G, Maroto JP, Calvo E, Cartwright TH, Loesch DM, Feit K, Das A, Zang EA, Wanders J, Agoulnik S, Petrylak DP. Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy. Ann Oncol 2012; 23:1241-1249. [PMID: 21903605 DOI: 10.1093/annonc/mdr380] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/06/2023] Open
Abstract
BACKGROUND Treatment options remain limited for patients with castration-resistant prostate cancer (CRPC). We evaluated eribulin mesylate (E7389), a nontaxane halichondrin B analog microtubule inhibitor, in patients with metastatic CRPC with or without previous taxane exposure. PATIENTS AND METHODS Men with histologically proven CRPC, with or without prior taxane exposure, were enrolled in an open-label, single-arm phase II trial. Patients received eribulin mesylate 1.4 mg/m(2) as a 2- to 5-min i.v. bolus infusion on days 1 and 8 of a 21-day cycle. The primary efficacy end point was prostate-specific antigen (PSA) response rate. RESULTS In total, 108 patients were assessable for safety (50 were taxane-pretreated) and 105 for efficacy in the per-protocol population. The median age of patients was 71 years and median number of cycles was 4. PSA decreases of ≥ 50% were achieved in 22.4% and 8.5% of taxane-naive and taxane-pretreated patients, respectively. The most common grade 3/4 adverse event was neutropenia, seen in 22.4% of chemo-naive and 40% of taxane-pretreated men. Grade 3 peripheral neuropathy occurred in none of the taxane-naive patients and 6.0% of taxane-pretreated patients. CONCLUSION Eribulin mesylate demonstrated activity and a relatively favorable toxicity profile in metastatic CRPC.
Collapse
Affiliation(s)
- J S de Bono
- Drug Development Unit, Royal Marsden Hospital/Institute of Cancer Research, Sutton, UK.
| | - L R Molife
- Drug Development Unit, Royal Marsden Hospital/Institute of Cancer Research, Sutton, UK
| | - G Sonpavde
- Texas Oncology, Houston; US Oncology, Houston, USA
| | - J P Maroto
- Department of Medical Oncology, Santa Creu I Sant Pau Hospital, Barcelona
| | - E Calvo
- Department of Medical Oncology, Vall d'Hebron Hospital, Barcelona, Spain
| | | | | | - K Feit
- Eisai Inc., Woodcliff Lake
| | - A Das
- Genentech Inc., South San Francisco, USA
| | | | | | | | - D P Petrylak
- Department of Medicine, Section of Medical Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, USA
| |
Collapse
|
42
|
Stadler WM, Vaughn DJ, Sonpavde G, Vogelzang NJ, Tagawa ST, Petrylak DP, Rosen PJ, Lin C, Mahoney JF, Modi SS, Lee P, Ernstoff MS, Su W, Spira AI, Ould Kaci M, Taube T, Vinisko R, Schloss C, Zhao C, Carducci MA. Clinical outcome of single agent volasertib (BI 6727) as second-line treatment of patients (pts) with advanced or metastatic urothelial cancer (UC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.4567] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
43
|
Slawin KM, Sonpavde G, McMannis JD, Bai Y, Seethammagari M, Bull JMC, Hawkins V, Dancsak T, Lapteva N, Levitt JM, Spencer DM. Results of a phase I/II clinical trial of BPX-101, a novel drug-activated dendritic cell (DC) vaccine for metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.4670] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
44
|
Chen GJ, Sonpavde G, Vale CL, Fisher D, Powles T. Association of progression-free survival (PFS) at 2 or 3 years with overall survival (OS) at 5 years for locally advanced bladder cancer (BC): Evaluation of individual patient data (IPD) from seven randomized trials comparing local therapy with or without neoadjuvant chemotherapy (NC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.4583] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
45
|
Lerner SP, Powles T, Hahn NM, Gardner T, Cheng L, Green J, Berney D, Taber D, Landgraf J, Shen SS, Sonpavde G. A phase II trial of neoadjuvant cisplatin (C), gemcitabine (G), and sunitinib (S) in muscle-invasive urothelial carcinoma (miUC): Results from Hoosier Oncology Group GU07-123 trial. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e15173] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
46
|
Hutson TE, Sarantopoulos J, Logan T, Sonpavde G, Galsky MD, Sweeney C, Bibby DC, Kremmidiotis G, Doolin EE, Hahn NM. Phase I/II study of BNC105P in combination with everolimus or following everolimus for progressive metastatic renal cell carcinoma following prior tyrosine kinase inhibitors. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.tps194] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
47
|
Fleming MT, Pond GR, Armstrong AJ, Wood BA, Brookes M, Leopold LH, Matveev VB, Burke JM, Caton JR, Sonpavde G. Ability of serum alkaline phosphatase (ALP) changes to complement PSA changes and predict survival in men with metastatic castration-resistant prostate cancer (mCRPC) receiving docetaxel and prednisone (DP). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e15019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
48
|
Galsky MD, Chen GJ, Oh WK, Bellmunt J, Roth BJ, Petrioli R, Dogliotti L, Dreicer R, Sonpavde G. Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e15027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
49
|
Berry WR, Fleming MT, Beer TM, Kolodziej MA, Awasthi S, Hutson TE, Martincic D, Wang Y, Asmar L, Sonpavde G. Association of rash with improved outcomes by the addition of cetuximab (C) to second-line mitoxantrone plus prednisone (MP) for progressive mCRPC after docetaxel-based chemotherapy. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e15040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
50
|
Sonpavde G, Matveev VB, Burke JM, Caton JR, Fleming MT, Karlov PA, Holmlund J, Wood BA, Brookes M, Leopold LH. A randomized, double-blind phase II trial of docetaxel plus prednisone (DP) combined with either AT-101 or placebo for the first-line therapy of metastatic castration-resistant prostate cancer (CRPC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.4528] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|